Table 1.
Attributes of the components within the LEISH-F3 or LEISH-F3+ fusion proteins
| Name | Source | Species conservation | Size (kD) | Potential HLA-binding motifs | Description | Notes and references |
|---|---|---|---|---|---|---|
| Nucleoside hydrolase | L. donovani | 100% L. infantum | 36 | None | Main immunogenic component of the fucose-mannose ligand (FML) complex of L. donovani | NH, formulated with saponin, protects mice against VL19 |
| — | 96% L. major | — | — | — | FML, formulated with QuilA saponin, protects dogs against VL20 | |
| — | 93% L. mexicana | — | — | — | — | |
| — | 92% L. tropica | — | — | — | — | |
| — | 84% L. braziliensis | — | — | — | — | |
| Sterol-24-c-methyl-transferase | L. infantum | 99% L. donovani | 40 | None | Involved in the biosynthesis of ergosterol (a membrane sterol in yeast and Leishmania spp.) | Protects mice against VL and CL when vaccinated subcutaneously with MPL-SE21, 22 |
| — | 97% L. major | — | — | — | — | |
| — | 94% L. mexicana | — | — | — | — | |
| — | 86% L. braziliensis | — | — | — | — | |
| Delta cysteine protease “B” | L. infantum | 99% L. donovani | 34 | None | Stage-regulated cathepsin-L-like cysteine protease (divergent carboxy-terminus aa#154-443) | Full length gene protects mice and dogs against VL when vaccinated using DNA prime and protein boost with CpG 9 |
| — | 68% L. major | — | aa1–aa153: sequence removed for vaccine subunit | — | — | |
| — | 73% L. mexicana | — | — | — | — | |
| — | 83% L. tropica | — | — | — | — | |
| — | 57% L. braziliensis | — | — | — | — |